Key points are not available for this paper at this time.
We investigated the efficacy and safety of dupilumab in Japanese patients aged ≥6 months to <18 years old with moderate-to-severe atopic dermatitis not adequately controlled with existing therapies.
Ebisawa et al. (2024) studied this question.